MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

How does cognition affect reaching in Parkinson’s disease?

J. Cosgrove, C. Picardi, S.L. Smith, S. Jamieson, J.E. Alty (Leeds, United Kingdom)

Meeting: 2016 International Congress

Abstract Number: 1401

Keywords: Motor control

Session Information

Date: Wednesday, June 22, 2016

Session Title: Parkinson's disease: Cognition

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To explore differences in kinematic parameters of reach in those with Parkinson’s disease (PD) classified into normal cognition (PD-NC), mild cognitive impairment (PD-MCI) and dementia (PDD).

Background: Reaching is a motor action controlled by a highly specialised neural pathway involving the posterior parietal and premotor frontal cortices. Reach has previously been studied in PD-NC and there is evidence of a greater reliance on visual feedback to guide the reaching arm compared to healthy controls (HC). Reach has not been studied in PD-MCI or PDD.

Methods: Twenty-two PD-NC, 23 PD-MCI, 10 PDD and 19 HC performed a reaching task under three conditions at a natural speed: a) full vision (FULL); b) towards an illuminated target in a darkened room (VIS); c) with eyes closed (MEM). All PD subjects were tested whilst on. Movement sensing equipment was used and calculated kinematic parameters were compared using standard statistical tests.

Results: Age, MDS-UPDRS Motor Score and levodopa equivalent daily dose were not significantly different between the PD groups. PDD had significantly longer duration of disease (p = 0.007) and average Montreal Cognitive Assessment score was significantly different between the PD groups (PD-NC 26.9, PD-MCI 22.1, PDD 17.6, p = <0.001). PD-NC had a significantly longer reach time (RT) compared to HC in MEM (p = <0.001) but not in FULL or VIS. PDD had the longest RT in all three conditions compared to PD-NC and PD-MCI with a trend towards significance in MEM (p = 0.081). In addition, time to attain peak acceleration, velocity and deceleration were significantly different between the PD groups in MEM and were longest for PDD (p = <0.05). There were no significant differences in kinematic reach parameters between PD-NC and PD-MCI in any condition.

Conclusions: The only condition that resulted in a slower reach for PD-NC compared to HC was when they had their eyes closed. The reaching movement profile of PDD differed significantly compared to PD-NC, particularly when visual input was omitted. These results suggest an increased reliance on visual feedback to guide reach in PD-NC compared to HC and in PDD compared to PD-NC. Impairment of visual spatial memory in PD may explain these findings, as may direct damage to the parietal reach region by infiltration of alpha-synuclein.

To cite this abstract in AMA style:

J. Cosgrove, C. Picardi, S.L. Smith, S. Jamieson, J.E. Alty. How does cognition affect reaching in Parkinson’s disease? [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/how-does-cognition-affect-reaching-in-parkinsons-disease/. Accessed June 23, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/how-does-cognition-affect-reaching-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • Life expectancy with and without Parkinson’s disease in the general population
    • The hardest symptoms that bother patients with Parkinson's disease
    • Patients with Essential Tremor Live Longer than their Relatives
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley